Karyopharm Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. HOOD
8. DFTX
9. MU
10. IBM

Go back to Karyopharm Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress

Karyopharm Therapeutics (KPTI) Misses Q4 EPS by 8c

February 15, 2023 7:35 AM EST

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q4 EPS of ($0.43), $0.08 worse than the analyst estimate of ($0.35). Revenue for the quarter came in at $33.6 million versus the consensus estimate of $35.25 million.

GUIDANCE:

Karyopharm Therapeutics sees FY2023 revenue of $160-175 million, versus the consensus of... More